Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653133 | 0.89 | SLC6A3 (0.41) | KCNH2GCKLMNASLC6A3 | |
| SCHEMBL2653272 | 0.86 | LMNA (0.43) | LMNASLC6A3 | |
| SCHEMBL2653002 | 0.85 | KCNH2 (0.44) | KCNH2GCKLMNAPTGDRTBXA2R | |
| SCHEMBL2651926 | 0.85 | KCNH2 (0.39) | KCNH2GCKLMNASLC6A3PIK3CD | |
| SCHEMBL2652100 | 0.80 | KCNH2 (0.53) | KCNH2GCKLMNA | |
| SCHEMBL6166444 | 0.80 | LMNA (0.43) | KCNH2GCKLMNA | |
| SCHEMBL2652305 | 0.76 | SLC6A3 (0.54) | LMNASLC6A3 | |
| SCHEMBL2668923 | 0.75 | KCNH2 (0.44) | KCNH2GCKLMNASLC6A3PIK3CD | |
| SCHEMBL2651736 | 0.75 | LMNA (0.42) | LMNASLC6A3 | |
| SCHEMBL2653506 | 0.74 | SLC6A3 (0.48) | KCNH2GCKLMNASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305301-B1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6608218-B2 | Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1305301-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-02 | — | — | EP | disclosed |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-12-26 | — | — | US | disclosed |
| US-6486184-B2 | 1-(CYCLOPENTYLOXY-(3,4-DICHLORO- PHENYL)-ACETYL)-3-METHYL-UREA FOR EXAMPLE; USE IN TREATING HYPERGLYCEMIA CHARACTERISTIC OF ALL TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2002008209-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | KCNH2 677/4885GCK 1/4885LMNA 4429/4885 |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | KCNH2 697/4885GCK 1/4885LMNA 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.